{"id":"W4409565762","doi":"10.1080/14796694.2025.2485015","title":"STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; Royal Ottawa Mental Health Centre","funders":"Exelixis; American Society of Clinical Oncology","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000225919,0.0002916528,0.0009437755,0.0003988595,0.0001034181,0.000007363181,0.0002108689,0.0003056101,0.0003641314],"category_scores_gemma":[0.00003069098,0.0002290514,0.0001123648,0.000771148,0.000152353,0.00006123436,0.0000997,0.0004143419,0.000003728445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006189631,"about_ca_system_score_gemma":0.0008343864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000399049,"about_ca_topic_score_gemma":0.001549264,"domain_scores_codex":[0.9979743,0.0001505918,0.0006638868,0.0004648973,0.0003476456,0.0003986717],"domain_scores_gemma":[0.9987823,0.0001143821,0.0002671482,0.0005376574,0.0002126638,0.00008584317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8727134,0.01770829,0.02253571,0.0001560359,0.001359733,0.0001522578,0.005414643,0.00001405311,0.0005170504,0.0001053026,0.00634996,0.07297358],"study_design_scores_gemma":[0.7384975,0.06428271,0.1059361,0.000178809,0.0005594638,0.00001433211,0.005205943,0.00002949429,0.0004329728,0.000007162636,0.08454674,0.0003087974],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848655,0.0006779713,0.000008267715,0.0007262509,0.001684661,0.001688902,0.0000196408,0.00004463297,0.01028418],"genre_scores_gemma":[0.9980012,0.00007836375,0.00009733869,0.0004360382,0.0002356846,0.00007111017,0.00007792454,0.00002712802,0.0009751825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1342159,"threshold_uncertainty_score":0.9340445,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01271133484206635,"score_gpt":0.3210914434739092,"score_spread":0.3083801086318428,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}